These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 21456032)

  • 21. Adalimumab dose escalation is effective and well tolerated in Crohn's disease patients with secondary loss of response to adalimumab.
    Duveau N; Nachury M; Gerard R; Branche J; Maunoury V; Boualit M; Wils P; Desreumaux P; Pariente B
    Dig Liver Dis; 2017 Feb; 49(2):163-169. PubMed ID: 27899263
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Mucosal expression of basic fibroblastic growth factor, syndecan 1 and tumour necrosis factor-α in Crohn's disease in deep remission under treatment with anti-TNFα antibodies.
    Tursi A; Elisei W; Principi M; Inchingolo CD; Nenna R; Picchio M; Giorgio F; Ierardi E; Brandimarte G
    J Gastrointestin Liver Dis; 2014 Sep; 23(3):261-5. PubMed ID: 25267953
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Azathioprine discontinuation earlier than 6 months in Crohn's disease patients started on anti-TNF therapy is associated with loss of response and the need for anti-TNF dose escalation.
    Viazis N; Koukouratos T; Anastasiou J; Giakoumis M; Triantos C; Tsolias C; Theocharis G; Karamanolis DG
    Eur J Gastroenterol Hepatol; 2015 Apr; 27(4):436-41. PubMed ID: 25874518
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Dose de-escalation to adalimumab 40 mg every 3 weeks in patients with Crohn's disease - a nested case-control study.
    Van Steenbergen S; Bian S; Vermeire S; Van Assche G; Gils A; Ferrante M
    Aliment Pharmacol Ther; 2017 Apr; 45(7):923-932. PubMed ID: 28164321
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Adalimumab safety in global clinical trials of patients with Crohn's disease.
    Colombel JF; Sandborn WJ; Panaccione R; Robinson AM; Lau W; Li J; Cardoso AT
    Inflamm Bowel Dis; 2009 Sep; 15(9):1308-19. PubMed ID: 19434735
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Adalimumab produces clinical remission and reduces extraintestinal manifestations in Crohn's disease: results from CARE.
    Löfberg R; Louis EV; Reinisch W; Robinson AM; Kron M; Camez A; Pollack PF
    Inflamm Bowel Dis; 2012 Jan; 18(1):1-9. PubMed ID: 21351211
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Systematic assessment of factors influencing preferences of Crohn's disease patients in selecting an anti-tumor necrosis factor agent (CHOOSE TNF TRIAL).
    Vavricka SR; Bentele N; Scharl M; Rogler G; Zeitz J; Frei P; Straumann A; Binek J; Schoepfer AM; Fried M;
    Inflamm Bowel Dis; 2012 Aug; 18(8):1523-30. PubMed ID: 21987429
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effects of infliximab retreatment after consecutive discontinuation of infliximab and adalimumab in refractory Crohn's disease.
    Brandse JF; Peters CP; Gecse KB; Eshuis EJ; Jansen JM; Tuynman HA; Löwenberg M; Ponsioen CY; van den Brink GR; DʼHaens GR;
    Inflamm Bowel Dis; 2014 Feb; 20(2):251-8. PubMed ID: 24378599
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Therapeutic strategy for Crohn's disease with a loss of response to infliximab: a single-center retrospective study.
    Nagata Y; Esaki M; Umeno J; Fuyuno Y; Ikegami K; Maehata Y; Asano K; Moriyama T; Nakamura S; Kitazono T; Matsumoto T
    Digestion; 2015; 91(1):50-6. PubMed ID: 25632918
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effects of adalimumab maintenance therapy on health-related quality of life of patients with Crohn's disease: patient-reported outcomes of the CHARM trial.
    Loftus EV; Feagan BG; Colombel JF; Rubin DT; Wu EQ; Yu AP; Pollack PF; Chao J; Mulani P
    Am J Gastroenterol; 2008 Dec; 103(12):3132-41. PubMed ID: 18853973
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Concomitant therapy with methotrexate and anti-TNF-α in pediatric patients with refractory crohn's colitis: a case series.
    Absah I; Faubion WA
    Inflamm Bowel Dis; 2012 Aug; 18(8):1488-92. PubMed ID: 21882301
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Adalimumab as second line anti-tumour necrosis factor alpha therapy for Crohn's disease: A single centre experience.
    Sprakes MB; Hamlin PJ; Warren L; Greer D; Ford AC
    J Crohns Colitis; 2011 Aug; 5(4):324-31. PubMed ID: 21683302
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Efficacy of adalimumab for the management of inflammatory bowel disease in the clinical setting.
    Trinder MW; Lawrance IC
    J Gastroenterol Hepatol; 2009 Jul; 24(7):1252-7. PubMed ID: 19220669
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Subgroup analysis of the placebo-controlled CHARM trial: increased remission rates through 3 years for adalimumab-treated patients with early Crohn's disease.
    Schreiber S; Reinisch W; Colombel JF; Sandborn WJ; Hommes DW; Robinson AM; Huang B; Lomax KG; Pollack PF
    J Crohns Colitis; 2013 Apr; 7(3):213-21. PubMed ID: 22704916
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Does weight-adjusted anti-tumour necrosis factor treatment favour obese patients with Crohn's disease?
    Bhalme M; Sharma A; Keld R; Willert R; Campbell S
    Eur J Gastroenterol Hepatol; 2013 May; 25(5):543-9. PubMed ID: 23337170
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Efficacy of adalimumab for the treatment of extraintestinal manifestations of Crohn's disease.
    Barreiro-de-Acosta M; Lorenzo A; Domínguez-Muñoz JE
    Rev Esp Enferm Dig; 2012 Sep; 104(9):468-72. PubMed ID: 23130854
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Predictors of efficacy, mucosal healing and dose intensification during the first year of adalimumab therapy in patients with luminal and fistulizing Crohn's disease. National data from Hungary].
    Kiss LS; Szamosi T; Molnár T; Miheller P; Lakatos L; Vincze A; Palatka K; Bartha Z; Gasztonyi B; Salamon A; Horváth G; Tóth GT; Farkas K; Banai J; Tulassay Z; Nagy F; Szenes M; Veres G; Lovász BD; Végh Z; Golovics PA; Szathmári M; Papp M; Lakatos PL
    Orv Hetil; 2011 Sep; 152(36):1433-42. PubMed ID: 21865144
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Adalimumab for Crohn's disease in clinical practice at Mayo clinic: the first 118 patients.
    Swoger JM; Loftus EV; Tremaine WJ; Faubion WA; Pardi DS; Kane SV; Hanson KA; Harmsen WS; Zinsmeister AR; Sandborn WJ
    Inflamm Bowel Dis; 2010 Nov; 16(11):1912-21. PubMed ID: 20848486
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Dose tailoring of anti-tumour necrosis factor-alpha therapy delivers useful clinical efficacy in Crohn disease patients experiencing loss of response.
    Ghaly S; Costello S; Beswick L; Pudipeddi A; Agarwal A; Sechi A; Antoniades S; Headon B; Connor S; Lawrance IC; Sparrow M; Walsh AJ; Andrews JM;
    Intern Med J; 2015 Feb; 45(2):170-7. PubMed ID: 25370691
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Medication effectiveness with the use of tumor necrosis factor inhibitors among Texas Medicaid patients diagnosed with rheumatoid arthritis.
    Oladapo A; Barner JC; Lawson KA; Novak S; Rascati KL; Richards KM; Harrison DJ
    J Manag Care Spec Pharm; 2014 Jul; 20(7):657-67. PubMed ID: 24967519
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.